Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach
Abstract Background Swertiamarin is the main hepatoprotective component of Swertiapatens and has anti-inflammatory and antioxidation effects. Our previous study showed that it was a potent inhibitor of idiopathic pulmonary fibrosis (IPF) and can regulate the expressions of α-smooth muscle actin (α-S...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2023-10-01
|
| Serija: | BMC Complementary Medicine and Therapies |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12906-023-04171-w |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|